Hatch-Waxman Integrity Act Introduced in US House and Senate


The Bill (H.R. 7251) would require companies desiring to launch a generic or biosimilar product to choose between an IPR and the Hatch-Waxman/BPCIA framework.


Members of the US House and Senate, on December 11, 2018, jointly introduced the Hatch-Waxman Integrity Act of 2018. Copies of the House and Senate Bill may be found here and here, respectively. If enacted, the Act would amend the FD&C and PHS Acts to require a generic (505(b)(2) or 505(j)) or biosimilar (351(k)) manufacturer wishing to challenge a brand-name drug patent to choose between: (i) an Inter Partes Review (IPR) before the Patent Trial and Appeal Board (PTAB) or (ii) the Hatch-Waxman (generic drugs) or BPCIA framework (biosimilars). Another portion of the Bill modifies the Securities and Exchange Act to penalize a person who undertakes a short sale of any publicly traded security of the owner of a patent that is the subject of an IPR petition.

Updates on the progress of this legislation will be provided.

For more information on our biopharma practice, please contact us.

Previous

Next